Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-trial

American Journal of Cardiology

Volumn 88, Issue 11, 2001, Pages 1240-1245

  Angeja, Brad G ^a,g   Alexander, John H ^b   Chin, Richard ^c   Li, Xin ^c   Barron, Hal V ^a,c   Armstrong, Paul W ^d   Granger, Christopher B ^b   Van De Werf, Frans ^e   Gibson, C Michael ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UCSF Medical Center at Parnassus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT;

AGED; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SAFETY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035578092     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02084-7     Document Type: Article

References (17)

1. A faster-acting and more potent form of tissue plasminogen activator
2. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators
3. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. The ASSENT-1 investigators
4. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial
5. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators
6. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis
7. Bolus fibrinolysis: Risk, benefit, and opportunities
8. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial
9. 1999 Update ACC/AHA Guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
10. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2
11. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial: Global use of strategies to open occluded coronary arteries
12. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients. GUSTO-I Investigators
13. The impact of low body weight in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2
14. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
15. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators
16. Time to therapy and salvage in myocardial infarction